Cambridge Healthtech Institute’s 13th Annual

Driving Clinical Success in Antibody-Drug Conjugates

Designing the Magic Bullet

May 18-19, 2023


Antibody-drug conjugates have shown a record number of approvals in the last 2 years. The resurgence of ADCs for cancer has propelled the industry to look into more diverse designs for the three key components – payloads, antibody (or not), and linkers. The Driving Clinical Success in Antibody-Drug Conjugates conference will invite speakers to present their ADC design and engineering, MOA investigation, preclinical to clinical outcomes, and combination strategies.


Coverage will include, but is not limited to:


  • Recent Approaches and Payload Selection in New ADC Design
  • Cytotoxic Payloads
    • PDD
    • DNA-damaging payloads
    • Folate receptor alpha
  • Immune-Stimulating Payloads
  • Non-Traditional Payloads
    • Antibody-Oligo Conjugates
    • Protein Degraders/PROTACs as payloads
  • Non-Antibody Binders
  • Novel Antibody Engineering & Conjugation


The deadline for priority consideration is October 21, 2022.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


Opportunities for Participation:



For more details on the conference, please contact:

Mimi Langley

Senior Conference Director

Cambridge Healthtech Institute

Phone: 781-972-5439



For sponsorship information, please contact:

Companies A-K

Jason Gerardi

Senior Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-5452



Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-1340